Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Vorolanib in Refractory Thoracic Tumors
NCT03583086Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jul 2018
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorolanib in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), thymic carcinoma (TC), sponsored by Vanderbilt-Ingram Cancer Center. Started Jul 2018; status: completed.
02
Drugs
vorolanib
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT03583086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583086.